Production (Stage)
Maze Therapeutics, Inc.
MAZE
$12.93
-$0.41-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -0.90% | -11.30% | -0.02% | -32.38% | |
| Total Depreciation and Amortization | -28.00% | -27.77% | -21.51% | -9.91% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -48.96% | -25.19% | 113.35% | 170.92% | |
| Change in Net Operating Assets | -672.29% | 145.86% | -643.30% | 109.90% | |
| Cash from Operations | -25.94% | -8.76% | -16.19% | -1.43% | |
| Capital Expenditure | -7.17% | -1,679.41% | -3,533.33% | -36.10% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -7.17% | -1,679.41% | -3,533.33% | -36.10% | |
| Total Debt Issued | -- | -100.00% | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 34,935.07% | 425.00% | 2,725.00% | 286.24% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 418.20% | 334.04% | -26,975.00% | 25,911.64% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 11,178.96% | 1,151.57% | -27.54% | 103.73% | |